Home-Based System Relieves Cirrhosis Refractory Ascites
|
By HospiMedica International staff writers Posted on 11 Jan 2022 |

Image: An ascites patient with abdominal paracentesis scars (Photo courtesy of iStock)
A novel tunneled peritoneal catheter (PeCa) drainage system provided significant relief for patients with refractory ascites, according to a new study.
The PeCa implant, developed at Hannover Medical School (Germany), is composed of internal shut that lies in the peritoneal cavity, a tunneled section that passes through subcutaneous tissue, and an external port to which drainage bags are connected. To test system efficacy, outcomes in 152 patients with refractory ascites, who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS) and received a PeCa implant, were compared to 71 patients who received standard care, which included repeated large volume paracentesis and albumin.
The results revealed that factors associated with 90-day survival were PeCa implantation, and each point of Model for End-Stage Liver Disease (MELD) score. Hospitalizations were more common in the PeCa group, for reasons that included spontaneous bacterial peritonitis (SBP), hyponatremia, and infections other than SBP. There was no significant difference in mortality between the two groups, but there were trends in the PeCa group towards higher frequency of acute kidney injury (AKI). The study was presented at the American Association for the Study of Liver Diseases annual conference, held online during November 2021.
“Patients with refractory ascites have a very high risk for rehospitalization, AKI, and death. Our data indicate that PeCa could be a valuable new treatment option for patients with refractory ascites and contraindication for TIPS,” said study co-author and presenter Tammo Lambert Tergast, MD. “I think if we can optimize the treatment after discharge, we can also minimize the rehospitalization in these patients. However, the risk for hyponatremia and AKI has to be considered and further explored.”
Refractory ascites occurs when patients no longer respond to medical therapy, a condition that affects over 100,000 patients in Europe and the United States every year, a number that is growing at approximately 10% a year. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5‐10 liters of ascites that has accumulated over a period of a week or two.
Related Links:
Hannover Medical School
The PeCa implant, developed at Hannover Medical School (Germany), is composed of internal shut that lies in the peritoneal cavity, a tunneled section that passes through subcutaneous tissue, and an external port to which drainage bags are connected. To test system efficacy, outcomes in 152 patients with refractory ascites, who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS) and received a PeCa implant, were compared to 71 patients who received standard care, which included repeated large volume paracentesis and albumin.
The results revealed that factors associated with 90-day survival were PeCa implantation, and each point of Model for End-Stage Liver Disease (MELD) score. Hospitalizations were more common in the PeCa group, for reasons that included spontaneous bacterial peritonitis (SBP), hyponatremia, and infections other than SBP. There was no significant difference in mortality between the two groups, but there were trends in the PeCa group towards higher frequency of acute kidney injury (AKI). The study was presented at the American Association for the Study of Liver Diseases annual conference, held online during November 2021.
“Patients with refractory ascites have a very high risk for rehospitalization, AKI, and death. Our data indicate that PeCa could be a valuable new treatment option for patients with refractory ascites and contraindication for TIPS,” said study co-author and presenter Tammo Lambert Tergast, MD. “I think if we can optimize the treatment after discharge, we can also minimize the rehospitalization in these patients. However, the risk for hyponatremia and AKI has to be considered and further explored.”
Refractory ascites occurs when patients no longer respond to medical therapy, a condition that affects over 100,000 patients in Europe and the United States every year, a number that is growing at approximately 10% a year. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5‐10 liters of ascites that has accumulated over a period of a week or two.
Related Links:
Hannover Medical School
Latest Patient Care News
- Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
- VR Training Tool Combats Contamination of Portable Medical Equipment
- Portable Biosensor Platform to Reduce Hospital-Acquired Infections
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
Channels
Artificial Intelligence
view channel
AI Model Identifies Rare Endocrine Disorder from Hand Images
Acromegaly is a rare, intractable disease that typically begins in middle age and causes enlargement of the hands and feet, changes in facial appearance, and abnormal bone and organ growth.... Read moreCritical Care
view channel
Spray-Type Technology Coats Transplant Organs with Immunosuppressants to Prevent Rejection
Organ transplantation is often the only life-saving option for patients with severe organ failure. However, immune rejection remains one of the biggest obstacles to successful transplantation.... Read more
Machine-Learning Model Predicts Preeclampsia in Late Pregnancy
Preeclampsia is a serious pregnancy complication marked by the sudden onset of high blood pressure before delivery. Affecting approximately 2% to 8% of pregnancies worldwide, the condition can lead to... Read more
Single Heart Attack Shot to Revolutionize Cardiac Care
Surviving a heart attack often marks the beginning of a long recovery period, during which the heart can remain vulnerable to damage and long-term weakening. Current treatments focus on stabilizing patients... Read more
Single Mid-Wave Infrared Thermal Camera Enables Noncontact Vital Signs Monitoring
Infrared thermal cameras are widely used to measure surface temperatures and have become common tools for fever screening during infectious disease outbreaks. However, body temperature alone often provides... Read moreSurgical Techniques
view channel
Surgical Robot Makes Complex Liver Tumor Surgery Safer and Less Invasive
Tumors located in the caudate lobe of the liver present a major surgical challenge. This deep section of the liver sits close to critical blood vessels, making traditional surgical access difficult and... Read more
Fluorescence Probe Paired with Engineered Enzymes Lights Up Tumors for Easier Surgical Removal
Successful cancer surgery relies on a surgeon’s ability to remove tumors while preserving as much healthy tissue as possible. To assist with this, surgeons often use fluorescent dyes that cause cancer... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Medtronic to Acquire Coronary Artery Medtech Company CathWorks
Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Medtronic and Mindray Expand Strategic Partnership to Ambulatory Surgery Centers in the U.S.
Mindray North America and Medtronic have expanded their strategic partnership to bring integrated patient monitoring solutions to ambulatory surgery centers across the United States. The collaboration... Read more
FDA Clearance Expands Robotic Options for Minimally Invasive Heart Surgery
Cardiovascular disease remains the world’s leading cause of death, with nearly 18 million fatalities each year, and more than two million patients undergo open-heart surgery annually, most involving sternotomy.... Read more







